In the rapidly evolving landscape of health technology, the line between a sophisticated fitness tracker and a medical diagnostic tool has become increasingly blurred. Deepinder Goyal, the former CEO of Eternal, has stepped into this contentious space with the launch of Temple, a wearable device that promises to provide users with unprecedented insights into their own physiology. For many, such devices represent the democratization of health data, offering a window into daily wellness that was once reserved for clinical settings. However, as the technology reaches the wrists of consumers, it has also invited intense scrutiny from those who have spent their careers navigating the rigorous, evidence-based world of medicine.
Behind the sleek exterior of the Temple device lies a substantial financial commitment. The company has poured approximately 30 million dollars into the research and development of the wearable, a figure that underscores the scale of the ambition behind the project. For Goyal, this investment is not merely a capital expenditure but a statement of intent regarding the potential for consumer-grade technology to influence personal health outcomes. Yet, the sheer volume of investment does not necessarily translate to clinical acceptance. In the medical community, the value of a device is measured not by its development budget, but by the peer-reviewed data that supports its diagnostic claims.
On November 6, 2026, the friction between tech innovation and medical skepticism reached a boiling point. Doctors, led by the vocal criticism of hepatologist Cyriac Abby Philips, began to publicly challenge the scientific validity of the metrics Temple claims to track. At the heart of the dispute is the device’s purported ability to assess brain-related metrics—a complex physiological area that typically requires specialized equipment and clinical oversight. For Dr. Philips and his peers, the prospect of a consumer device providing data on such sensitive metrics without established clinical validation is not just premature; it is a potential risk to public health, as users may misinterpret wellness data as medical advice.
He maintains that the device is intended to function within the realm of lifestyle and wellness, rather than as a substitute for professional medical intervention.
Facing a growing chorus of critics, Goyal has sought to clarify the positioning of his product. He maintains that the device is intended to function within the realm of lifestyle and wellness, rather than as a substitute for professional medical intervention. "Templ is a fitness tracker and wellness device. We are not a medical device," Goyal stated, echoing his firm stance that the product serves a different purpose than the diagnostic tools used in hospitals. By framing Temple as a wellness tool, the company attempts to navigate the regulatory and ethical complexities that come with monitoring human biology. However, this distinction remains a point of contention for those who argue that the marketing of such devices often implies a level of medical precision that the underlying technology has yet to prove.
Facing growing scrutiny over his wearable device ‘Temple’, Deepinder Goyal defended the product, citing his decision to step down as Eternal CEO and invest ₹282.55 crore in its development. https://t.co/hz5wxNZpOQ
Despite the pushback, the company remains committed to its trajectory. Temple has openly acknowledged that it has not yet clinically validated all of its metrics, promising to disclose such validation as it becomes available. In the interim, the company is leaning on a 14-day return policy to manage consumer expectations and mitigate the risks of early adoption. Goyal remains optimistic, suggesting that the true value of the science behind the product will be validated over time, both by the lived experiences of its users and through the ongoing research efforts of his team. As the debate continues, the case of Temple serves as a compelling case study in the modern era of health tech: a high-stakes test of whether a product can earn the trust of the medical establishment while simultaneously capturing the imagination of the consumer market.